Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

KRAS amplification

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

KRAS deletion (1)

KRAS deletion (1)

›

KRAS amplification	Melanoma	KRAS amplification	Melanoma	sorafenib Sensitive: B - Late Trials sorafenib Sensitive : B	sorafenib Sensitive: B - Late Trials sorafenib Sensitive : B
KRAS amplification	Colorectal Cancer	KRAS amplification	Colorectal Cancer	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3
KRAS amplification	Colorectal Cancer	KRAS amplification	Colorectal Cancer	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3
KRAS amplification	Colorectal Cancer	KRAS amplification	Colorectal Cancer	panitumumab Resistant: C3 – Early Trials panitumumab Resistant : C3	panitumumab Resistant: C3 – Early Trials panitumumab Resistant : C3
KRAS amplification	Germ Cell Tumors	KRAS amplification	Germ Cell Tumors	MEK inhibitor Sensitive: C3 – Early Trials MEK inhibitor Sensitive : C3	MEK inhibitor Sensitive: C3 – Early Trials MEK inhibitor Sensitive : C3
KRAS amplification	Non Small Cell Lung Cancer	KRAS amplification	Non Small Cell Lung Cancer	lorlatinib Resistant: C3 – Early Trials lorlatinib Resistant : C3	lorlatinib Resistant: C3 – Early Trials lorlatinib Resistant : C3
KRAS amplification	Pancreatic Cancer	KRAS amplification	Pancreatic Cancer	binimetinib Resistant: D – Preclinical binimetinib Resistant : D	binimetinib Resistant: D – Preclinical binimetinib Resistant : D